Evidence map›Paper›PMID 39933590›Full record

ArticleJournal of applied microbiology2025

Antimicrobial activity of peptoids against Metallo-β-lactamase-producing Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and other WHO priority pathogens, including Candida auris.

Shyam Kumar Mishra, Muhammad Yasir, Rajesh Kuppusamy, Edgar H H Wong, Alex Hui, Kristian Sørensen, Jennifer S Lin, Håvard Jenssen, Annelise E Barron, Mark Willcox

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of applied microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Shyam Kumar MishraSchool of Optometry and Vision Science, Faculty of Medicine and Health, University of New South Wales, Sydney, NSW 2052, Australia.ORCID 0000-0002-3888-7319
Muhammad YasirSchool of Optometry and Vision Science, Faculty of Medicine and Health, University of New South Wales, Sydney, NSW 2052, Australia.
Rajesh KuppusamySchool of Optometry and Vision Science, Faculty of Medicine and Health, University of New South Wales, Sydney, NSW 2052, Australia.
Edgar H H WongSchool of Chemical Engineering, Faculty of Engineering, University of New South Wales, Sydney, NSW 2052, Australia.
Alex HuiSchool of Optometry and Vision Science, Faculty of Medicine and Health, University of New South Wales, Sydney, NSW 2052, Australia.
Kristian SørensenDepartment of Bioengineering, School of Medicine and School of Engineering, Stanford University, Stanford, CA 94305, USA.
Jennifer S LinDepartment of Bioengineering, School of Medicine and School of Engineering, Stanford University, Stanford, CA 94305, USA.
Håvard JenssenDepartment of Science and Environment, Roskilde University, Roskilde 4000, Denmark.
Annelise E BarronDepartment of Bioengineering, School of Medicine and School of Engineering, Stanford University, Stanford, CA 94305, USA.
Mark WillcoxSchool of Optometry and Vision Science, Faculty of Medicine and Health, University of New South Wales, Sydney, NSW 2052, Australia.ORCID 0000-0003-3842-7563

Funding

Danish Council for Independent Research #4005-00029NHMRC APP1183597NIH HHS 1DP1 OD029517SENS Research FoundationSilicon Valley Community Foundation
6 · The paper itself

Abstract

aimsThe World Health Organization has identified ESKAPE bacteria and Candida auris as priority pathogens, emphasizing an urgent need for novel antimicrobials to combat them. This study aimed to explore the therapeutic potential of antimicrobial peptidomimetics, specifically peptoids with sequence-specific N-substituted glycines, against ESKAPEE pathogens, including metallo-β-lactamase (MBL) producers, as well as C. auris strains. METHODS AND

resultsThis study evaluated activity of the peptoids against the multidrug-resistant priority pathogens. The peptoid TM8 (with an N-decyl alkyl chain) demonstrated a geometric mean minimum inhibitory concentration (MIC) of 7.8 μg ml-1 against MBL-producing bacteria, and 5.5 μg ml-1 against C. auris. TM8 showed synergy with ciprofloxacin, enhancing its effectiveness 4-fold against NDM-1-producing Klebsiella pneumoniae. No antagonism was seen when TM8 was used with either conventional antibiotics or antifungals. Peptoids that had therapeutic indices below 3 were generally more hydrophobic, due to either alkyl chains or bromine. Scanning electron microscopy and live-dead staining assay on peptoid-treated C. auris confirmed morphological changes and killing activity, respectively. Furthermore, the peptoid could effectively inhibit biofilm formation by C. auris.

conclusionPeptoids demonstrated antibacterial activity against ESKAPEE, particularly against MBL-producing Gram-negative bacteria. Additionally, they exhibited antifungal and anti-biofilm activities against C. auris strains.

Indexed as

Acinetobacter baumanniiAnti-Bacterial AgentsCandida aurisKlebsiella pneumoniaePeptoidsPseudomonas aeruginosaAntifungal Agentsbeta-LactamasesBiofilmsDrug Resistance, Multiple, BacterialHumansMicrobial Sensitivity TestsAnti-Bacterial AgentsAntifungal Agentsbeta-LactamasesPeptoidsbiofilmCandida aurisESKAPEE pathogensmetallo-β-lactamasemultidrug resistancepeptidomimeticsynergy

Identifiers

PMID39933590
PMCPMC11879280

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.